GLIPIZIDE | A074223 | WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition Completeness Assessment Correspondence from FDA CDER to ... FDA-2023-P-4443 · 7 docket documents Hyman, Phelps & McNamara, P.C. filed a suitability petition under 21 C.F.R. §314.93(b) requesting permission to submit an Abbreviated New Drug Application for Glipizide Tablets, 15 mg, and the FDA determined the petition was complete with a review goal date of April 23, 2024, under the Generic Drugs | Suitability | 2023-10-23 | Granted | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0457
per ea
Lowest NADAC/Unit
$0.0351
per ea
Brand NDCs
0
Generic NDCs
6
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00591046101GLIPIZIDE 10 MG TABLET | $0.0457 | EA | Generic | — | 2026-06-17 |
| 00591046105GLIPIZIDE 10 MG TABLET | $0.0457 | EA | Generic | — | 2026-06-17 |
| 00591046110GLIPIZIDE 10 MG TABLET | $0.0457 | EA | Generic | — | 2026-06-17 |
| 00591046001GLIPIZIDE 5 MG TABLET | $0.0351 | EA | Generic | — | 2026-06-17 |
| 00591046005GLIPIZIDE 5 MG TABLET | $0.0351 | EA | Generic | — | 2026-06-17 |
| 00591046010GLIPIZIDE 5 MG TABLET | $0.0351 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.